Fig. 1 · Structure

Documents & Downloads

MG-115

Cat. No. A11601 CAS 133407-86-0

Reversible Proteasome Inhibitor

MG-115 is a potent, reversible peptide aldehyde inhibitor of proteasome chymotrypsin-like and caspase-like activities. It induces p53 dependent apoptosis.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

MG-115 Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of MG-115 from 3 published references. In vitro models include EL-4 T cells; BSB8 cells.

MG-115 In Vitro Studies

In EL-4 T cells, MG-115 pretreatment had no effect on basal accessibility in nonstimulated cells. In P/I-stimulated cells, MG-115 reduced the increase in accessibility compared with cells without MG-115 pretreatment. In BSB8 cells, comparison of MG-115 with DMSO control showed that MG-115 failed to rescue T-Ag degradation even in cells overexpressing Bag3. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Basal accessibility in nonstimulated T cells

Cell-based study · EL-4 T cells [1]

EL-4 T cells were pretreated with MG-115. Treatment had no effect on the inherent basal level of accessibility in nonstimulated cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
inherent basal level of accessibility seen in nonstimulated cellsReported result The MG-115 inhibitor had no effect on the inherent basal level of accessibility seen in nonstimulated cells[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM
Exposure duration
pretreated for 1 h with the proteasome inhibitor MG115, then incubated with or without P/I for 4 h
Method
pretreated
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: MG-115

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Cell Culture and Preparation of Stable Cell Lines. (S7); Results > Remodeling of the GM-CSF Promoter Is Dependent on NF-κB Proteins. (S86, S87); Figure 4. legend (S172)

inherent basal level of accessibility seen in nonstimulated cells: inherent basal level of accessibility seen in nonstimulated cells; comparator: untreated — Results > Remodeling of the GM-CSF Promoter Is Dependent on NF-κB Proteins. (S87)

T antigen degradation in cells overexpressing Bag3

Cell-based study · BSB8 cells [2]

BSB8 cells were treated with MG-115 or DMSO control in a design involving a Bag3 expression plasmid. MG-115 failed to rescue T-Ag degradation even in cells overexpressing Bag3.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Western blot analysis was performed for the detection of Large T, and Bag3 proteinsReported result failed to rescue degradation of T-Ag even in cells overexpressing Bag3[2]

Literature-Reported Treatment Conditions

Treatment concentration
30 µM
Exposure duration
At 24 hours post-transfections; Cells were treated for 24 hours
Method
treatment media
Vehicle
DMSO
Co-treatment
Other interventions in this design: expression plasmid encoding Bag3. Compound effect isolated by the comparison: MG-115 or DMSO (control).
Methods and source locations

Compound reported in the paper: MG-115

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Post-transcriptional Suppression of T-Ag by Bag3 is Independent from Proteasomal Pathway (S26); Materials and Methods > Inhibitors and Treatments (S90, S91); Figure 3 legend (S148, S149)

Western blot analysis was performed for the detection of Large T, and Bag3 proteins: Western blot analysis was performed for the detection of Large T, and Bag3 proteins; comparator: DMSO (control) — Results > Post-transcriptional Suppression of T-Ag by Bag3 is Independent from Proteasomal Pathway (S26); Figure 3 legend (S149)

Accessibility changes in stimulated T cells

Cell-based study · EL-4 T cells [1]

EL-4 T cells were untreated or pretreated with MG-115, then incubated with or without P/I. In P/I-stimulated cells, MG-115 reduced the increase in accessibility.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
The percentage change in accessibility in 4 h P/I stimulated nuclei compared with nonstimulated nucleichromatin accessibility almost fourfold[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM
Exposure duration
pretreated for 1 h with the proteasome inhibitor MG115, then incubated with or without P/I for 4 h
Method
pretreated
Co-treatment
Other interventions in this design: PMA 20 ng/ml; calcium ionophore 1 μM. Compound effect isolated by the comparison: EL-4 T cells were either untreated or pretreated for 1 h with the proteasome inhibitor MG115, then incubated with or without P/I for 4 h..
Reported limits
Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: MG-115

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Cell Culture and Preparation of Stable Cell Lines. (S6, S7); Materials and Methods > Chromatin Accessibility by Real-Time PCR. (S16, S17); Results > Remodeling of the GM-CSF Promoter Is Dependent on NF-κB Proteins. (S86, S88); Figure 4. legend (S172, S173, S174)

The percentage change in accessibility in 4 h P/I stimulated nuclei compared with nonstimulated nuclei: The percentage change in accessibility in 4 h P/I stimulated nuclei compared with nonstimulated nuclei; comparator: untreated — Results > Remodeling of the GM-CSF Promoter Is Dependent on NF-κB Proteins. (S88); Figure 4. legend (S174)

MG-115 In Vivo Studies

Mice received MG-115 by infusion into the right ventricle at 0.1 mg/ml for 4 weeks, with vehicle as the control. MG-115 significantly prevented NEFM degradation but had no effect on the degradation of NEFL, NEFH, or GAPDH. [3]

Neurofilament degradation in mice

Animal study · C57BL/6J mice; 9-month-old mice (n = 3 for each treatment) [3]

Mice received MG-115 by infusion into the right ventricle at 0.1 mg/ml for 4 weeks. MG-115 significantly prevented NEFM degradation but had no effect on the degradation of NEFL, NEFH, or GAPDH.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
NF protein levels were measured in cortex/hippocampus by immunoblot analysesNF protein levels 0.1 mg/ml, 4 weeks duration: NEFM 1.408 ± 0.035 (fold increase)[3]

Conditions shared by the study groups

Route
ICV Infusion; into the right ventricle
Treatment course
4 weeks; 0.25 µl/h delivery rate
Vehicle
25% DMSO containing 20 mM HEPES, pH 7.4
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
MG-115 0.1 mg/mlvehicleNEFM: 1.408 ± 0.035 (fold increase); MG115 significantly prevented the degradation of NEFM but had no effect on the degradation of NEFL, NEFH, and GAPDH[3]
MG-115 0.1 mg/ml
Model: C57BL/6J mice; 9-month-old mice (n = 3 for each treatment)
Methods and source locations

Compound reported in the paper: MG-115

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > MG-115 infusion slows only NEFM proteolysis in mouse brain (S79, S81); Materials and methods > Intracerebroventricular (ICV) infusion of 3-MA and MG-115 (S98); Figure 7. legend (S193, S194); Table 2. (T2.h1, T2.h2, T2.r2)

NF protein levels were measured in cortex/hippocampus by immunoblot analyses: NF protein levels were measured in cortex/hippocampus by immunoblot analyses; comparator: vehicle — Results > MG-115 infusion slows only NEFM proteolysis in mouse brain (S79, S81); Table 2. (T2.h1, T2.h2, T2.r2)

MG-115 0.1 mg/ml · Results > MG-115 infusion slows only NEFM proteolysis in mouse brain (S79, S81); Materials and methods > Intracerebroventricular (ICV) infusion of 3-MA and MG-115 (S98); Figure 7. legend (S193); Table 2. (T2.h1, T2.h2, T2.r2)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 133407-86-0
Applications Reversible Proteasome Inhibitor
Formula C25H39N3O5
Molecular Weight 461.59
Synonyms Carbobenzoxy-L-leucyl-L-leucyl-L-norvalinal; Z-LL-Nva-CHO; Proteasome Inhibitor XII,MG115
SMILES
O=C(N[C@H](C(N[C@@H](CC(C)C)C(N[C@H](C([H])=O)CCC)=O)=O)CC(C)C)OCC1=CC=CC=C1

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

MG-115 Research References

  1. [1] Holloway AF, Rao S, Chen X, et al. Changes in chromatin accessibility across the GM-CSF promoter upon T cell activation are dependent on nuclear factor kappaB proteins. J Exp Med (2003). PMID: 12591900 DOI: 10.1084/jem.20021039 Source material
  2. [2] Sariyer IK, Merabova N, Patel PK, et al. Bag3-induced autophagy is associated with degradation of JCV oncoprotein, T-Ag. PLoS One (2012). PMID: 22984599 DOI: 10.1371/journal.pone.0045000 Source material
  3. [3] Rao MV, Darji S, Stavrides PH, et al. Autophagy is a novel pathway for neurofilament protein degradation in vivo. Autophagy (2023). PMID: 36131358 DOI: 10.1080/15548627.2022.2124500 Source material

Added to your cart

View Cart Checkout
Loading...